PriceTargets.com logo

Exact Sciences - EXAS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $72.94
  • Forecasted Upside: 22.79%
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 17 Buy Ratings
  • 0 Strong Buy Ratings
$59.40 As of 12/20/2024 06:51 PM ET
▲ +3.29 (5.86%)

This chart shows the closing price for EXAS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Exact Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EXAS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXAS

Analyst Price Target is $72.94
▲ +22.79% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $72.94, with a high forecast of $90.00 and a low forecast of $60.00. The average price target represents a 22.79% upside from the last price of $59.40.

This chart shows the closing price for EXAS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 18 contributing investment analysts is to moderate buy stock in Exact Sciences. This rating has held steady since September 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 18 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 17 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/13/2024Bank of AmericaLower TargetBuy ➝ Buy$75.00 ➝ $72.00
11/26/2024TD CowenBoost TargetBuy ➝ Buy$82.00 ➝ $86.00
11/26/2024BTIG ResearchBoost TargetBuy ➝ Buy$65.00 ➝ $75.00
11/21/2024William BlairReiterated RatingOutperform
11/11/2024Piper SandlerLower TargetOverweight ➝ Overweight$85.00 ➝ $75.00
11/6/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$84.00 ➝ $85.00
11/6/2024CitigroupLower TargetBuy ➝ Buy$80.00 ➝ $75.00
11/6/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$95.00 ➝ $75.00
11/6/2024Stifel NicolausLower TargetBuy ➝ Buy$82.00 ➝ $67.00
11/6/2024BTIG ResearchLower TargetBuy ➝ Buy$82.00 ➝ $65.00
11/6/2024Evercore ISILower TargetOutperform ➝ Outperform$80.00 ➝ $60.00
11/6/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$75.00 ➝ $65.00
11/6/2024TD CowenLower TargetBuy ➝ Buy$90.00 ➝ $82.00
11/6/2024BenchmarkLower TargetBuy ➝ Buy$67.00 ➝ $65.00
11/6/2024Craig HallumLower TargetBuy ➝ Buy$82.00 ➝ $65.00
11/6/2024Robert W. BairdLower TargetOutperform ➝ Outperform$70.00 ➝ $67.00
10/30/2024Sanford C. BernsteinBoost TargetOutperform ➝ Outperform$75.00 ➝ $90.00
10/29/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$75.00 ➝ $95.00
10/1/2024Evercore ISIBoost TargetOutperform ➝ Outperform$72.00 ➝ $80.00
9/26/2024Raymond JamesReiterated RatingMarket Perform
9/13/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
9/12/2024Piper SandlerBoost TargetOverweight ➝ Overweight$75.00 ➝ $85.00
8/27/2024Wells Fargo & CompanyInitiated CoverageOverweight$75.00
8/1/2024BenchmarkLower TargetBuy ➝ Buy$91.00 ➝ $67.00
8/1/2024Stifel NicolausLower TargetBuy ➝ Buy$100.00 ➝ $82.00
7/17/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$88.00 ➝ $75.00
7/2/2024Evercore ISILower TargetOutperform ➝ Outperform$80.00 ➝ $72.00
6/27/2024ScotiabankInitiated CoverageSector Outperform$70.00
6/26/2024BTIG ResearchLower TargetBuy ➝ Buy$80.00 ➝ $70.00
6/3/2024Jefferies Financial GroupInitiated CoverageBuy$75.00
5/9/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$90.00 ➝ $85.00
5/9/2024BTIG ResearchLower TargetBuy ➝ Buy$85.00 ➝ $80.00
5/9/2024CitigroupLower TargetBuy ➝ Buy$100.00 ➝ $80.00
4/3/2024CitigroupReiterated RatingBuy ➝ Buy$100.00
2/22/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$100.00 ➝ $90.00
2/22/2024William BlairReiterated RatingOutperform
1/8/2024William BlairReiterated RatingOutperform
1/2/2024BenchmarkUpgradeHold ➝ Buy$91.00
12/14/2023GuggenheimInitiated CoverageBuy$90.00
12/13/2023Wolfe ResearchInitiated CoverageOutperform$95.00
11/3/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$100.00 ➝ $90.00
11/2/2023William BlairReiterated RatingOutperform
10/16/2023Piper SandlerLower TargetOverweight ➝ Overweight$90.00 ➝ $80.00
10/10/2023Piper SandlerUpgradeNeutral ➝ Overweight$90.00
9/28/2023Sanford C. BernsteinInitiated CoverageOutperform$83.00
8/8/2023Piper SandlerBoost TargetNeutral ➝ Neutral$80.00 ➝ $90.00
8/3/2023Jefferies Financial GroupBoost TargetBuy ➝ Buy$100.00 ➝ $110.00
8/2/2023Bank of AmericaBoost Target$105.00 ➝ $110.00
8/2/2023Credit Suisse GroupBoost TargetNeutral ➝ Neutral$75.00 ➝ $90.00
8/2/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$99.00 ➝ $121.00
8/2/2023BenchmarkDowngradeBuy ➝ Hold
7/21/2023The Goldman Sachs GroupBoost TargetBuy$85.00 ➝ $110.00
6/22/2023Stifel NicolausBoost Target$85.00 ➝ $120.00
6/22/2023Craig HallumBoost Target$85.00 ➝ $106.00
6/22/2023BTIG ResearchBoost Target$95.00 ➝ $110.00
6/22/2023CitigroupBoost Target$100.00 ➝ $130.00
6/22/2023BenchmarkBoost Target$81.00 ➝ $96.00
6/7/2023Jefferies Financial GroupBoost Target$82.00 ➝ $100.00
5/15/2023Piper SandlerBoost Target$70.00 ➝ $80.00
5/11/2023CitigroupBoost Target$90.00 ➝ $100.00
5/10/2023Stifel NicolausBoost Target$75.00 ➝ $85.00
5/10/2023BTIG ResearchBoost Target$80.00 ➝ $90.00
5/10/2023Bank of AmericaBoost Target$80.00 ➝ $88.00
5/10/2023Robert W. BairdBoost Target$92.00 ➝ $99.00
5/10/2023Craig HallumUpgradeHold ➝ Buy$55.00 ➝ $85.00
5/5/2023UBS GroupInitiated CoverageNeutral$73.00
3/15/2023BenchmarkBoost TargetBuy$54.00 ➝ $78.00
3/9/2023CitigroupUpgradeNeutral ➝ Buy$70.00 ➝ $90.00
3/3/2023Piper SandlerBoost TargetNeutral$50.00 ➝ $70.00
2/22/2023Craig HallumBoost Target$44.00 ➝ $55.00
2/22/2023Canaccord Genuity GroupBoost TargetBuy$70.00 ➝ $75.00
2/22/2023CowenBoost TargetOutperform$56.00 ➝ $76.00
2/22/2023Robert W. BairdBoost TargetOutperform$89.00 ➝ $92.00
2/22/2023BTIG ResearchLower TargetBuy$85.00 ➝ $80.00
2/22/2023Credit Suisse GroupReiterated RatingNeutral$70.00
2/22/2023CitigroupBoost TargetNeutral$35.00 ➝ $70.00
2/10/2023Credit Suisse GroupDowngradeOutperform ➝ Neutral$50.00 ➝ $70.00
1/18/2023Raymond JamesDowngradeOutperform ➝ Market Perform
1/12/2023Leerink PartnersBoost TargetOutperform$70.00 ➝ $75.00
1/9/2023Craig HallumBoost Target$35.00 ➝ $44.00
1/6/2023Leerink PartnersBoost TargetOutperform$60.00 ➝ $70.00
11/14/2022Piper SandlerBoost TargetNeutral$40.00 ➝ $50.00
11/7/2022Raymond JamesLower TargetOutperform$70.00 ➝ $60.00
11/7/2022BTIG ResearchLower TargetBuy$70.00 ➝ $65.00
11/4/2022Robert W. BairdLower Target$75.00 ➝ $60.00
11/4/2022CitigroupLower Target$50.00 ➝ $35.00
10/19/2022Craig HallumDowngradeBuy ➝ Hold$60.00 ➝ $35.00
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$55.00
8/17/2022Piper SandlerLower TargetOverweight$50.00 ➝ $40.00
8/9/2022Evercore ISIBoost Target$65.00
8/9/2022BenchmarkLower Target$54.00
8/3/2022Raymond JamesLower TargetOutperform$80.00 ➝ $70.00
8/3/2022CitigroupLower TargetNeutral$65.00 ➝ $50.00
8/3/2022Robert W. BairdLower TargetOutperform$90.00 ➝ $75.00
8/3/2022BTIG ResearchLower TargetBuy$100.00 ➝ $70.00
8/3/2022CowenLower TargetOutperform$83.00 ➝ $67.00
8/3/2022CowenLower TargetOutperform$83.00 ➝ $67.00
8/3/2022Craig HallumLower TargetBuy$81.00 ➝ $60.00
7/19/2022CowenSet Target$83.00
6/2/2022Piper SandlerInitiated CoverageNeutral$50.00
4/27/2022Craig HallumLower Target$100.00 ➝ $81.00
4/27/2022Robert W. BairdLower Target$100.00 ➝ $90.00
4/27/2022Raymond JamesLower Target$90.00 ➝ $80.00
4/27/2022CitigroupLower Target$80.00 ➝ $65.00
4/19/2022The Goldman Sachs GroupLower TargetBuy$100.00 ➝ $85.00
2/23/2022Craig HallumLower Target$133.00 ➝ $100.00
2/23/2022Raymond JamesLower TargetOutperform$130.00 ➝ $90.00
2/23/2022Wells Fargo & CompanyLower TargetEqual Weight$95.00 ➝ $80.00
2/23/2022Robert W. BairdLower Target$116.00 ➝ $100.00
2/23/2022CitigroupLower TargetNeutral$100.00 ➝ $80.00
2/23/2022Leerink PartnersLower TargetOutperform$140.00 ➝ $130.00
11/3/2021BTIG ResearchLower TargetPositive ➝ Buy$145.00 ➝ $120.00
11/3/2021Craig HallumLower TargetBuy$144.00 ➝ $133.00
11/3/2021Leerink PartnersLower TargetOutperform$160.00 ➝ $140.00
11/3/2021Wells Fargo & CompanyLower TargetEqual Weight$120.00 ➝ $95.00
11/3/2021Robert W. BairdLower TargetOutperform$125.00 ➝ $116.00
11/3/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$160.00 ➝ $130.00
10/14/2021CowenLower TargetOutperform$160.00 ➝ $135.00
7/29/2021Stifel NicolausLower TargetBuy$165.00 ➝ $145.00
7/29/2021BTIG ResearchLower TargetBuy$155.00 ➝ $145.00
7/29/2021OppenheimerLower TargetOutperform$161.00 ➝ $155.00
7/29/2021Robert W. BairdLower TargetOutperform$157.00 ➝ $127.00
7/14/2021Leerink PartnersLower TargetOutperform$170.00 ➝ $160.00
6/21/2021Wells Fargo & CompanyBoost TargetEqual Weight$115.00 ➝ $120.00
6/15/2021Raymond JamesInitiated CoverageStrong-Buy$160.00
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$160.00
5/25/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$115.00
5/12/2021Truist FinancialLower TargetBuy$226.00 ➝ $168.00
5/5/2021Craig HallumLower TargetBuy$161.00 ➝ $144.00
5/5/2021BTIG ResearchLower TargetBuy$175.00 ➝ $155.00
5/5/2021Leerink PartnersLower TargetOutperform$180.00 ➝ $170.00
2/18/2021Robert W. BairdLower TargetOutperform$169.00 ➝ $163.00
2/17/2021Stifel NicolausBoost TargetBuy$150.00 ➝ $165.00
2/17/2021Leerink PartnersBoost TargetMarket Perform ➝ Outperform$170.00 ➝ $180.00
2/17/2021CowenBoost TargetOutperform$154.00 ➝ $180.00
1/27/2021Truist FinancialInitiated CoverageBuy$226.00 ➝ $226.00
1/21/2021Leerink PartnersBoost TargetOutperform$160.00 ➝ $170.00
10/29/2020UBS GroupDowngradeBuy ➝ Neutral$125.00 ➝ $140.00
10/28/2020OppenheimerBoost Target$115.00 ➝ $150.00
10/28/2020BTIG ResearchBoost Target$140.00 ➝ $155.00
10/28/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$120.00 ➝ $140.00
10/28/2020Robert W. BairdBoost TargetPositive ➝ Outperform$135.00 ➝ $150.00
10/28/2020Leerink PartnersBoost TargetOutperform$115.00 ➝ $160.00
10/28/2020BenchmarkBoost TargetBuy$110.00 ➝ $145.00
7/31/2020Leerink PartnersBoost TargetOutperform$90.00 ➝ $115.00
7/31/2020BenchmarkBoost TargetBuy$90.00 ➝ $110.00
7/31/2020CitigroupBoost TargetBuy$110.00 ➝ $120.00
7/8/2020OppenheimerReiterated RatingBuy
6/25/2020CitigroupBoost TargetBuy$100.00 ➝ $110.00
5/7/2020Robert W. BairdBoost TargetOutperform$90.00 ➝ $92.00
5/7/2020Bank of AmericaBoost TargetBuy$88.00 ➝ $94.00
5/7/2020Craig HallumLower TargetIn-Line ➝ Buy$99.00 ➝ $92.00
5/7/2020Leerink PartnersLower TargetOutperform$100.00 ➝ $90.00
4/28/2020UBS GroupLower TargetBuy$135.00 ➝ $115.00
4/22/2020CitigroupLower TargetBuy$120.00 ➝ $100.00
4/22/2020Robert W. BairdLower TargetOutperform$100.00 ➝ $90.00
4/21/2020OppenheimerReiterated RatingBuy$115.00
4/17/2020Craig HallumLower TargetBuy$127.00 ➝ $99.00
4/2/2020Stifel NicolausLower TargetBuy$110.00 ➝ $90.00
4/2/2020Evercore ISIInitiated CoverageOutperform$70.00
2/14/2020Stifel NicolausReiterated RatingBuy$110.00
2/12/2020Robert W. BairdReiterated RatingBuy
1/10/2020BTIG ResearchInitiated CoverageBuy$127.00
1/6/2020CitigroupInitiated CoverageBuy$120.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.13 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 23 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 22 very positive mentions
  • 5 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
6/24/2024
  • 19 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 19 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 22 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
9/22/2024
  • 22 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 29 very positive mentions
  • 22 positive mentions
  • 8 negative mentions
  • 2 very negative mentions
Mentions as of
11/21/2024
  • 33 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 33 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Exact Sciences logo
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Read More

Today's Range

Now: $59.40
Low: $55.98
High: $59.70

50 Day Range

MA: $61.91
Low: $49.33
High: $71.93

52 Week Range

Now: $59.40
Low: $40.62
High: $79.62

Volume

3,273,828 shs

Average Volume

2,615,913 shs

Market Capitalization

$10.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Exact Sciences?

The following Wall Street analysts have issued reports on Exact Sciences in the last year: Bank of America Co., Benchmark Co., BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Craig Hallum, Evercore ISI, Jefferies Financial Group Inc., Piper Sandler, Raymond James, Robert W. Baird, Sanford C. Bernstein, Scotiabank, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Inc., TheStreet, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for EXAS.

What is the current price target for Exact Sciences?

0 Wall Street analysts have set twelve-month price targets for Exact Sciences in the last year. Their average twelve-month price target is $72.94, suggesting a possible upside of 22.8%. Sanford C. Bernstein has the highest price target set, predicting EXAS will reach $90.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $60.00 for Exact Sciences in the next year.
View the latest price targets for EXAS.

What is the current consensus analyst rating for Exact Sciences?

Exact Sciences currently has 1 hold rating and 17 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for EXAS.

What other companies compete with Exact Sciences?

Other companies that are similar to Exact Sciences include Alnylam Pharmaceuticals, Biogen, United Therapeutics, Neurocrine Biosciences and Incyte. Learn More about companies similar to Exact Sciences.

How do I contact Exact Sciences' investor relations team?

Exact Sciences' physical mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company's listed phone number is (608) 284-5700 and its investor relations email address is [email protected]. The official website for Exact Sciences is www.exactsciences.com. Learn More about contacing Exact Sciences investor relations.